• 407-549-3929
  • info@gapsos.com
Latest Peer Review Articles by our Clinical and Medical Team at Global Allied Pharmaceuticals

Immunotherapy and Glioblastoma Multiforme

Download GBM is the most common primary brain tumor. As per the World Health Organization (WHO), GBM is classified as grade IV glioma. GBM is invasive and penetrates the adjoining brain tissue. Incidence is higher in case of men and […]

Read More

IMMUNOTHERAPY AND HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma (HCC) is considered the most common primary cancer of the liver. HCC accounts for 90% of all liver cancers.HCC is the fifth common cause of cancer in men and seventh in women worldwide. It is the second most […]

Read More

Immunotherapy and gastroenteropancreatic neuroendocrine tumor

Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) originates from the hormone producing cells of the gut along with rectum and pancreas. GEP-NET represents 75% of all neuroendocrine tumors (NETs). The incidence is 2.5 to 6.2 cases per 100,000 population and 5-year mean survival […]

Read More

IMMUNOTHERAPY AND MALIGNANT PLEURAL MESOTHELIOMA

Malignant pleural mesothelioma is an aggressive type of cancer in which cancerous cells are found in the lining of the abdomen or chest that occurs due to asbestos exposure in the mesothelium. According to the National Cancer Institute’s Surveillance, Epidemiology […]

Read More

IMMUNOTHERAPY AND PANCREATIC CANCER

Integrative Gastroenterology and Hepatology Immunotherapy and Pancreatic Cancer Allen T* , Shoja G and Court NB Global Allied Pharmaceuticals, Center for Excellence in Research and Development, USA * Correspondence: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and […]

Read More

IMMUNOTHERAPY AND MENINGIOMA

Immunotherapy and Meningioma Timothy Allen*, Ariel Sheikkhon, Shoja E Razavi, Naveed Basha Court Global Allied Pharmaceuticals, Center for Excellence in Research and Development, USA. timallenmed69@gmail.com *Corresponding Author: Timothy Allen, Global Allied Pharmaceuticals, Center for Excellence in Research and Development, 160 […]

Read More

Immunotherapy and penis cancer

Abstract Penis cancer, a cancerous disease in which malignant cells appear in the tissues of the penis. It occurs in the uncircumcised older men. It is recognized by at least two independent carcinogenic routes: virus and non-virus induced. The penis […]

Read More

Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy

Download Abstract Diffuse large B-cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately 60,000 new non-Hodgkin lymphoma (NHL) cases and 20,000 deaths have been estimated in the United States for […]

Read More

Frontline Treatment in Diffuse Large B-Cell Lymphoma(DLBCL) and the Futuristic Alternate Standard of Care for the First Line Therapy

Download Abstract Diffuse large B cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately 60,000 new non-Hodgkin lymphoma (NHL) cases and 20,000 deaths have been estimated in the United States […]

Read More

Malignant melanoma

Abstract Download Worldwide incidence of malignant melanoma has been constantly increasing during the last years. Surgical excision is effective when primary tumors are thin with thickness of less than 1milli meter and there is no evidence of metastases. At later […]

Read More
Page 1 of 7
1 2 3 7
Stay in Touch with us by ...

Subscribe to our Newsletter